Reviewing Forward Pharma A/S (FWP)’s and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB)’s results

Both Forward Pharma A/S (NASDAQ:FWP) and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Forward Pharma A/S N/A 0.00 29.41M -0.28 0.00
AmpliPhi Biosciences Corporation N/A 532.85 10.14M -0.76 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Forward Pharma A/S and AmpliPhi Biosciences Corporation.


Table 2 shows us Forward Pharma A/S and AmpliPhi Biosciences Corporation’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Forward Pharma A/S 0.00% -7.8% -6.5%
AmpliPhi Biosciences Corporation 0.00% -118.6% -84.7%

Volatility and Risk

Forward Pharma A/S has a beta of 2.8 and its 180.00% more volatile than Standard & Poor’s 500. Competitively, AmpliPhi Biosciences Corporation’s beta is 2.74 which is 174.00% more volatile than Standard & Poor’s 500.


The current Quick Ratio of Forward Pharma A/S is 17.2 while its Current Ratio is 17.2. Meanwhile, AmpliPhi Biosciences Corporation has a Current Ratio of 2.1 while its Quick Ratio is 2.1. Forward Pharma A/S is better positioned to pay off its short-term and long-term debts than AmpliPhi Biosciences Corporation.

Insider & Institutional Ownership

The shares of both Forward Pharma A/S and AmpliPhi Biosciences Corporation are owned by institutional investors at 20.9% and 6.5% respectively. Comparatively, 1.28% are AmpliPhi Biosciences Corporation’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Forward Pharma A/S 0.47% 28.38% 26.05% -53.78% -51.35% 77.76%
AmpliPhi Biosciences Corporation 4.29% 4.9% 17.35% -72.88% -80.15% 30.83%

For the past year Forward Pharma A/S’s stock price has bigger growth than AmpliPhi Biosciences Corporation.


On 5 of the 7 factors Forward Pharma A/S beats AmpliPhi Biosciences Corporation.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults. Its pipeline also includes AB-PA01 for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis and chronic rhinosinusitis patients. AmpliPhi Biosciences Corporation has a research collaboration agreement with Royal Brompton Hospital; a license agreement with University of Leicester to develop a phage therapy that targets and kills various clinically relevant toxin types of C. difficile; a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research to develop and commercialize bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and a clinical trial agreement with the University of Adelaide. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.